For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Aclaris Therapeutics Inc (NASDAQ: ACRS) closed at $2.27 up 0.44% from its previous closing price of $2.26. In other words, the price has increased by $0.44 from its previous closing price. On the day, 2.84 million shares were traded. ACRS stock price reached its highest trading level at $2.6389 during the session, while it also had its lowest trading level at $2.195.
Ratios:
For a deeper understanding of Aclaris Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.88 and its Current Ratio is at 3.88. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On May 28, 2025, Wedbush started tracking the stock assigning a Outperform rating and target price of $8.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 19 ’24 when Mehra Anand bought 666,666 shares for $2.25 per share. The transaction valued at 1,499,998 led to the insider holds 710,030 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 245914128 and an Enterprise Value of 147390816. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.65 while its Price-to-Book (P/B) ratio in mrq is 1.87. Its current Enterprise Value per Revenue stands at 8.779 whereas that against EBITDA is -2.53.
Stock Price History:
The Beta on a monthly basis for ACRS is 0.66, which has changed by -0.14393938 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, ACRS has reached a high of $5.17, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 11.23%, while the 200-Day Moving Average is calculated to be 30.51%.
Shares Statistics:
For the past three months, ACRS has traded an average of 1.09M shares per day and 1469020 over the past ten days. A total of 108.33M shares are outstanding, with a floating share count of 92.30M. Insiders hold about 14.80% of the company’s shares, while institutions hold 73.50% stake in the company. Shares short for ACRS as of 1760486400 were 4689649 with a Short Ratio of 4.29, compared to 1757894400 on 5821942. Therefore, it implies a Short% of Shares Outstanding of 4689649 and a Short% of Float of 5.1599998000000005.
Earnings Estimates
The company has 5.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.12 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$0.51 and -$0.62 for the fiscal current year, implying an average EPS of -$0.55. EPS for the following year is -$0.63, with 5.0 analysts recommending between -$0.49 and -$0.87.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $1.44M this quarter.It ranges from a high estimate of $2.1M to a low estimate of $700k. As of. The current estimate, Aclaris Therapeutics Inc’s year-ago sales were $4.35MFor the next quarter, 6 analysts are estimating revenue of $1.44M. There is a high estimate of $1.97M for the next quarter, whereas the lowest estimate is $700k.
A total of 7 analysts have provided revenue estimates for ACRS’s current fiscal year. The highest revenue estimate was $7.2M, while the lowest revenue estimate was $2.6M, resulting in an average revenue estimate of $5.29M. In the same quarter a year ago, actual revenue was $18.72MBased on 7 analysts’ estimates, the company’s revenue will be $5.5M in the next fiscal year. The high estimate is $10M and the low estimate is $2M.
